SCHEMBL30976409

SCHEMBL30976409

Cn1nc(C(=O)N2CCN(C(=O)OC(C)(C)C)CC2)c2cc(Br)ccc2c1=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
ATM Q13315 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
ALDH1A1 P00352 4/20 0.46
MAPT P10636 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
GAA P10253 3/20 0.45
NPC1 O15118 1/20 0.45
LMNA P02545 1/20 0.45
NR2F2 P24468 1/20 0.45
HTT P42858 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
POLB P06746 3/20 0.41
KRAS P01116 1/20 0.41
BACE1 P56817 4/20 0.41
RECQL P46063 1/20 0.40
TSHR P16473 1/20 0.39
KDM4E B2RXH2 1/20 0.39
DTYMK P23919 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30976241 0.87 MEN1 (0.50) MEN1KMT2AATML3MBTL1ALDH1A1
SCHEMBL30976335 0.87 MEN1 (0.51) MEN1KMT2AATML3MBTL1ALDH1A1
SCHEMBL30976347 0.85 MEN1 (0.69) MEN1KMT2AATML3MBTL1ALDH1A1
SCHEMBL30976251 0.84 MEN1 (0.51) MEN1KMT2AATML3MBTL1ALDH1A1
SCHEMBL30976476 0.82 MEN1 (0.51) MEN1KMT2AATML3MBTL1ALDH1A1
SCHEMBL23535396 0.77 ELANE (0.45) MEN1KMT2ANPC1LMNAPOLB
SCHEMBL30976334 0.77 POLB (0.54) MEN1KMT2AATML3MBTL1ALDH1A1
SCHEMBL30976257 0.74 ALDH1A1 (0.44) MEN1KMT2AATML3MBTL1ALDH1A1
SCHEMBL30976451 0.72 L3MBTL1 (0.56) MEN1KMT2AATML3MBTL1ALDH1A1
SCHEMBL2928630 0.71 KMT2A (0.68) MEN1KMT2AALDH1A1LMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260027113-A1 PHTHALAZINONE BASED MODULATORS FOR THE TREATMENT OF DISEASE SOLEY THERAPEUTICS INC (US) 2026-01-29 US disclosed
US-12465603-B2 Phthalazinone based modulators for the treatment of disease SOLEY THERAPEUTICS, INC. (US) 2025-11-11 US disclosed
EP-4619387-A1 PHTHALAZINONE BASED MODULATORS FOR THE TREATMENT OF DISEASE Soley Therapeutics, Inc. (US) 2025-09-24 EP disclosed
US-20240374589-A1 PHTHALAZINONE BASED MODULATORS FOR THE TREATMENT OF DISEASE SOLEY THERAPEUTICS, INC. 2024-11-14 US disclosed
WO-2024108131-A1 PHTHALAZINONE BASED MODULATORS FOR THE TREATMENT OF DISEASE SOLEY THERAPEUTICS, INC. (US) 2024-05-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12465603-B2 Phthalazinone based modulators for the treatment of disease MKI67, BCL2, CCAR2 MEN1 1555/4885KMT2A 1305/4885ATM 2793/4885
US-20260027113-A1 PHTHALAZINONE BASED MODULATORS FOR THE TREATMENT OF DISEASE NCOR1, NOP56, NCOR2 MEN1 2848/4885KMT2A 3358/4885ATM 2985/4885
US-20240374589-A1 PHTHALAZINONE BASED MODULATORS FOR THE TREATMENT OF DISEASE MKI67, HDAC6, BCL2 MEN1 1629/4885KMT2A 2242/4885ATM 2828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.